• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

News

Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells

17 de June de 2026
Cell Death Dis. 2026 Jun 17. doi: 10.1038/s41419-026-08992-8.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-17 10:00:002026-06-17 10:00:00Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells

Epigenetic Clocks in the Cosmic Silence of a Deep Underground Laboratory: Implications for Aging and Space Exploration

15 de June de 2026
Aging Dis. 2026 Jun 5. doi: 10.14336/AD.2026.0468. Online ahead…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-15 10:00:002026-06-15 10:00:00Epigenetic Clocks in the Cosmic Silence of a Deep Underground Laboratory: Implications for Aging and Space Exploration

Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study

15 de June de 2026
Leukemia. 2026 Jun 15. doi: 10.1038/s41375-026-02993-4. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-15 10:00:002026-06-15 10:00:00Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study

Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study

12 de June de 2026
Pol Arch Intern Med. 2026 Jun 12:17320. doi: 10.20452/pamw.17320.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-12 10:00:002026-06-12 10:00:00Long-term outcomes of sirolimus therapy in sporadic and tuberous sclerosis complex-associated lymphangioleiomyomatosis: a retrospective cohort study

Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes

11 de June de 2026
Support Care Cancer. 2026 Jun 11;34(7):645. doi: 10.1007/s00520-026-10874-w.ABSTRACTPURPOSE:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-11 10:00:002026-06-11 10:00:00Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes

Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy

8 de June de 2026
Clin Cancer Res. 2026 Jun 8. doi: 10.1158/1078-0432.CCR-26-0601.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-08 10:00:002026-06-08 10:00:00Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapy

Editorial: Current insights in melanoma immunology, immune escape and immunotherapy advances

8 de June de 2026
Front Immunol. 2026 May 18;17:1868805. doi: 10.3389/fimmu.2026.1868805.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-08 10:00:002026-06-08 10:00:00Editorial: Current insights in melanoma immunology, immune escape and immunotherapy advances

The Exciting World of Neptune Casino Bonuses

7 de June de 2026
The world of online gaming continues to evolve, and neptune casino…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 Susana https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg Susana2026-06-07 11:37:212026-09-14 09:50:22The Exciting World of Neptune Casino Bonuses

Cellular Senescence in the Absence of Galactic Cosmic-Ray Muons

3 de June de 2026
Aging Dis. 2026 May 18. doi: 10.14336/AD.2026.0025. Online ahead…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-03 10:00:002026-06-03 10:00:00Cellular Senescence in the Absence of Galactic Cosmic-Ray Muons

Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

3 de June de 2026
Bone Marrow Transplant. 2026 Jun 3. doi: 10.1038/s41409-026-02914-0.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-06-03 10:00:002026-06-03 10:00:00Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee

Wino Casino Advantages: A Closer Look

3 de June de 2026
Wino Casino stands out in the online gaming industry, offering…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 Susana https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg Susana2026-06-03 04:14:262026-09-14 09:50:30Wino Casino Advantages: A Closer Look

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

27 de May de 2026
Bone Marrow Transplant. 2026 May 27. doi: 10.1038/s41409-026-02919-9.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-05-27 10:00:002026-05-27 10:00:00The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy
Page 5 of 88«‹34567›»

Filter by categories

  • Alemany’s & Piulats’s lab (135)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (112)
  • Sin categoría (12)
  • Sureda's & Farre's Lab (319)
  • Viñals's lab (113)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}